Rising Prevalence of CVD is Escalating the Global Cardiac Arrest Treatment Market

The global cardiac arrest treatment market is projected to exhibit a significant growth, at a CAGR of around 5.4%, during the forecast period. The rising cases of hypertension or blood pressure around the globe are spurring the growth of the cardiac arrest treatment market. According to the World Health Organization (WHO), approximately 1.13 billion people across the globe suffer from hypertension, in which less than one in five people with hypertension have the problem under control. Hypertension can be a critical cause for premature death across the globe. One of the global targets for noncommunicable diseases is to decrease the pervasiveness of hypertension by 25.0% by 2025. 

Browse the full report description Global Cardiac Arrest Treatment Market Size, Share & Trends Analysis Report by Treatment (Drugs and Medical Devices) and Forecast 2020-2026 at https://www.omrglobal.com/industry-reports/cardiac-arrest-treatment-market

Over the past two decades, fatalities due to heart diseases including hypertension have been declining in the developed economies; however, it has been increasing at an alarming rate in emerging economies. Improved access to the individual healthcare interventions along with population-wide measures can result in a significant reduction in the health as well as socioeconomic caused by CVD diseases and their risk factors.  At the same time, the healthcare systems in several emerging economies are let down by the model based on the hospital care focused on disease treatment, often centered around the high technology hospitals that offer extensive treatments for only a small group of citizens.

Further, according to the National Center for Biotechnology Information and US National Library of Medicine, hypertension associated deaths are likely to increase from approximately 7.5 million in 2010 to 1.56 billion deaths in 2050, annually across the globe. As per the American Heart Society, in the US in 2017 the fatality rate of hypertension was approximately 9.0% over other CVDs. Heart diseases such as CVD, CHD; among other heart diseases are the leading causes of mortalities across the globe. According to WHO, around 17.9 million fatalities occur each year due to heart diseases, which is estimated to be around 31.0% of the global fatalities. Amongst these fatalities, around 7.4 million had CHD and approx. 6.7 million fatalities occurred due to a stroke. 

By 2030, it has been projected that CVDs will be responsible for around 23.6 million mortalities across the globe. Around 80.0% of the deaths caused due to CVD take place in low-middle income group regions, such as Africa, Latin America, and Asia-Pacific. Excessive consumption of alcohol and tobacco, unhealthy diet, and sedentary lifestyle are the major factors that are giving rise to the incidence and prevalence rates of heart diseases. The rapidly increasing prevalence of heart diseases also leads to an alarming number of fatalities around the globe and the trend is expected to continue in the future. Such increasing prevalence of hypertension will further spur the cardiac arrest market during the forecast period.

Global Cardiac Arrest Treatment Market-Segmentation

By Treatment

• Drugs

o Vasopressors

o Corticosteroids

o Anti-arrhythmic Drugs

o Others (Beta blockers and Fibrinolytic drugs)

• Medical Devices

o Defibrillators

o Cardiac Resynchronization Therapy (CRT)

o Others (Ventricular Assist Devices (VADs))

Global Cardiac Arrest Treatment Market– Segment by Region